Dualitas Therapeutics is a biotechnology company pioneering the future of bispecific antibody therapies for immune and inflammatory (I&I) diseases and beyond. Powered by our proprietary DualScreen™ discovery engine and a growing library of novel cell surface proximity engagers, our pipeline—including lead programs DTX-103 and DTX-102—has demonstrated compelling preclinical evidence supporting its potential to address important unmet patient needs. We offer partnering opportunities on the next generation of bispecific therapies in I&I diseases – and beyond. Notice on Fraudulent Job Offers and Recruiting Activities: Dualitas Therapeutics has been made aware of fraudulent recruiting activity in which individuals falsely claim to represent our company. These scammers may offer fake job opportunities and attempt to collect personal or financial information. All legitimate communication from Dualitas comes from email addresses ending in @dualitastx.com Our only official website is www.dualitastx.com, and our official LinkedIn page is linkedin.com/company/dualitas-therapeutics. Any other domains, pages, or variations should be considered suspicious. Dualitas does not conduct interviews through text or messaging apps, does not ask candidates to download software, does not request payments or financial information, and does not issue job offers without in‑person interviews.
| Website | https://www.dualitastx.com |
| Employees | 19 (7 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
Looking for a particular Dualitas Therapeutics employee's phone or email?
Forbes Huang is the Co-Founder, COO and CBO of Dualitas Therapeutics.
7 people are employed at Dualitas Therapeutics.